Dr Randall M Johnson, MD | |
184 Us Highway 41 E, Negaunee, MI 49866-9606 | |
(906) 315-2607 | |
(906) 475-9312 |
Full Name | Dr Randall M Johnson |
---|---|
Gender | Male |
Speciality | Preventive Medicine - Public Health & General Preventive Medicine |
Location | 184 Us Highway 41 E, Negaunee, Michigan |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1265517155 | NPI | - | NPPES |
1862351 | Medicaid | MI | |
2671990 | Medicaid | MI | |
5100662 | Medicaid | MI | |
3903600261 | Other | MI | BCBS OF MI PROVIDER ID |
0521038 | Other | MI | BCC PROVIDER ID |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2083P0901X | Preventive Medicine - Public Health & General Preventive Medicine | RJ040842 (Michigan) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Randall M Johnson, MD 184 Us Highway 41 E, Negaunee, MI 49866-9606 Ph: (906) 315-2607 | Dr Randall M Johnson, MD 184 Us Highway 41 E, Negaunee, MI 49866-9606 Ph: (906) 315-2607 |
News Archive
NanoBio Corporation has announced that it has seen promising results from an interim analysis of its phase 2 study of NB-002, a topical lotion for onychomycosis (nail fungus). Although the details remain confidential, the results clearly justify completing the study, according to NanoBio scientists
The University of Tennessee Health Science Center's Office of Research announced that annual research grant and contract awards for FY21, which ended June 30, total more than $121 million, a 20.6% increase from last year.
Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis.
Acorda Therapeutics, Inc. today announced that data from the second of two pivotal dalfampridine extended release tablets Phase 3 clinical trials in multiple sclerosis (MS) were published in the October 2010 edition of Annals of Neurology.
› Verified 4 days ago